All News

Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.

An expert from the Smilow Cancer Hospital and Yale Cancer Center indicates that findings from the ctDNA analysis of the phase 3 INTRIGUE study were “provocative” and that the subsequent phase 3 INSIGHT study has the potential to be practice changing should data be positive.

Findings from a phase 2 trial indicate that CTX-009 plus paclitaxel may produce an encouraging responses in patients with advanced biliary tract cancer, according to investigators.

Neoadjuvant pembrolizumab appears to improve outcomes in a cohort of patients with metastatic microsatellite instability–high, mismatch repair deficient solid tumors.

Trial results presented at a recent medical conference demonstrated that the use of shorter duration radiation is safe and effective in prostate cancer, as well as a type of rare cancer, according to an expert.

Treatment with nivolumab plus ipilimumab appears to result in overall survival and progression-free survival benefit in patients with intermediate- or poor-risk sarcomatoid renal cell carcinoma.

DB-1303, an investigational third generation antibody-drug conjugate that now has FDA fast track designation, may benefit patients with HER2-overexpressing endometrial cancer.

Data from the phase 2 PIONEER trial supports the supplemental new drug application for avapritinib in adult patients with indolent systemic mastocytosis, an uncontrolled proliferation and activation of mast cells.

Findings from the phase 3 BREAKWATER study indicate that encorafenib plus cetuximab and chemotherapy produces activity and is well-tolerated in metastatic colorectal cancer harboring BRAF V600E mutations.

Findings from the phase 2 MOUNTAINEER trial indicate that HER2 scoring algorithms may help in identifying which patients are suitable to receive tucatinib plus trastuzumab for metastatic colorectal cancer.

Data presented at a recent medical conference shows that there is continued interest in observing the effects of fewer radiation treatments across several cancer types, according to an expert.

Findings from the phase 3 SUNLIGHT study highlight favorable overall survival and disease control rates with the use of bevacizumab plus trifluridine and tipiracil in metastatic colorectal cancer.

Under a new FDA initiative, the agency recently updated a decades’ old approval of the chemotherapy capecitabine. This move, according to an expert, will springboard further change in the treatment of cancer.

An expert from Augusta University says cancer care should extend beyond treatment and highlights why unmet social needs should be a consideration for survivors of hematologic cancer, especially those with a lower socioeconomic status or who are of a racial or ethnic minority.

Adjuvant atezolizumab plus bevacizumab may effectively combat recurrence after surgery in patients with early-stage hepatocellular carcinoma.

Hun Ju Lee, MD, reviews results from part C of the phase 2 SGN35-27 trial for patients with early-stage classical Hodgkin lymphoma treated with brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine.

Novel, personalized, tumor-informed brPROPHET technology can assess molecular residual disease with greater sensitivity than other assays, according to initial data.

Patients with hepatocellular carcinoma treated from 2018 to 2021 experienced better outcomes than patients treated in the preceding decade, according to a recent study.

Molecular responders by G360 response algorithm with advanced colorectal cancer appear to have significantly lengthened time on treatment and overall survival with all regimens vs patients who did not respond.

An expert from the Mayo Clinic discusses how findings from the ongoing phase 3 MOUNTAINEER trial may enable access to tucatinib, trastuzumab, and chemotherapy in earlier lines of treatment for patients with HER2-positive metastatic colorectal cancer.

Investigators report evidence of early efficacy with SEA-CD40, chemotherapy, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

Patients with advanced biliary tract cancer experience modest clinical benefit following treatment with atezolizumab and cisplatin/gemcitabine with or without bevacizumab.

Patients diagnosed with locally advanced, hepatocellular carcinoma experience benefit in overall survival, progression-free survival, and time to disease progression following treatment with sorafenib and stereotactic body radiation therapy.

Patients with newly diagnosed, advanced biliary tract cancers do not have a statistically significant survival benefit following treatment with nab-paclitaxel plus gemcitabine and cisplatin.

A combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline yields a statistically significant survival benefit compared with nab-paclitaxel and gemcitabine in a population diagnosed with metastatic pancreatic ductal adenocarcinoma.

Patients with unresectable hepatocellular carcinoma experienced an improvement in several health-related quality of life measures following treatment with first-line tislelizumab compared with sorafenib.

Lenvatinib in combination with blank-microsphere transarterial chemembolization and sequential microwave ablation demonstrates encouraging preliminary activity in patients with hepatocellular carcinoma.

Envafolimab in combination with lenvatinib and transarterial chemoembolization demonstrated efficacy and safety among patients with unresectable hepatocellular carcinoma.

Findings from the phase 3 HIMALAYA trial indicate that durvalumab with or without tremelimumab remained efficacious regardless of the presence of anti-drug antibodies in unresectable hepatocellular carcinoma.

Findings from the phase 3 LEAP-002 study indicate that the addition of pembrolizumab to lenvatinib did not impact quality-of-life scores among patients with hepatocellular carcinoma.